Institutional Zambon Pharma February 26, 2025 Massimo Grandi joins Zambon as Chief Core Therapies Officer
Institutional ZCube September 24, 2024 Zcube - Zambon Research Venture leads a C$2 million investment round in canadian startup Hyivy Health
Institutional ZCube September 23, 2024 Open Accelerator: Zcube announces 5 Startups Selected for the New Edition Focused on Women’s Health and Femtech
Scientific Zambon Pharma September 13, 2024 Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa
Institutional Zambon Pharma May 2, 2024 Giovanni Magnaghi is the new Chief Executive Officer of Zambon SpA
Scientific Zambon Biotech February 27, 2024 Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
Institutional ZCube February 27, 2024 Zcube Launches the 2024 Edition of Open Accelerator, an International Acceleration Program Aimed at Life Sciences Startups with Focus on Women's Health and Femtech
Scientific Zambon Pharma July 18, 2023 Zambon Presents Results from the Two Phase 3 PROMIS Studies of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis at World Bronchiectasis Conference 2023
